Tobira Therapeutics, Inc

93 articles about Tobira Therapeutics, Inc

• Tobira Therapeutics Inc. Raises $31 Million in Series B Financing

  9/30/2010

• Tobira Therapeutics Inc.'s Next-Generation Once-Daily CCR5/CCR2 Antagonist Demonstrates Potent CCR2 Inhibition, Antiviral Activity, Safety and Tolerability in Treatment-Experienced Patients With HIV

  7/19/2010

• Pharmacokinetic/Pharmacodynamic Data Support Further Development of Tobira Therapeutics Inc.'s Next-Generation CCR5 Receptor Antagonist

  2/18/2010

• Tobira Therapeutics Inc. Announces Presentation of TBR-652 Data at European AIDS Conference

  11/12/2009

• Tobira Therapeutics Inc. Announces In Vitro Data of TBR-652 for the Treatment of HIV

  9/14/2009

• Tobira Therapeutics Inc. Announces In Vitro Data of TBR-652 for the Treatment of HIV

  9/14/2009

• Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV

  7/22/2009

• Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board

  6/4/2009

• Tobira Therapeutics Inc. Initiates Proof of Concept Study with TAK-652 for the Treatment of HIV

  4/9/2009

• Tobira Therapeutics Inc. to Present at the 2008 Biotechnology Industry Organization (BIO) Investor Forum

  10/24/2008

• Tobira Therapeutics Inc. Receives US Patent for TBR-652

  8/18/2008

• Tobira Therapeutics Inc. Announces Senior Management Team

  6/30/2008

• Tobira Therapeutics Inc. Completes $31 Million Series A Financing; Names CEO

  8/2/2007